{"entity":{"id":"magdolna-dank","kind":"person","name":"Magdolna Dank","aka":[],"tldr":"Hungarian oncologist who is Director-General of the National Institute of Oncology in Budapest, Hungary's national cancer centre.","summary":"Professor Magdolna Dank is Director-General and Chief Physician (Foigazgato Foorvos) of the National Institute of Oncology (Orszagos Onkologiai Intezet) in Budapest, Hungary's national comprehensive cancer centre. She heads a directorate that includes a medical director, a scientific director and a nursing director. Her welcome message on the institute's home page introduces her in the role of Director-General.","asOf":"2026-09-10","links":[{"label":"Source: National Institute of Oncology directors page","url":"https://onkol.hu/igazgatok/"}],"tags":["leadership","clinician-scientist","medical-oncology"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["noi-budapest"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["lancet-oncology","nature-communications"],"dependsOn":[],"notes":[],"role":"Director-General and Chief Physician, National Institute of Oncology, Budapest","institutionId":"noi-budapest","specialisms":["Clinical oncology","Medical oncology","Cancer centre management"],"profiles":[{"label":"Institute directors page","url":"https://onkol.hu/igazgatok/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Dank+M%5BAuthor%5D"}],"papers":[{"title":"Are Calculated Immune Markers with or Without Comorbidities Good Predictors of Colorectal Cancer Survival? The Results of a Longitudinal Study","journal":"Medical Sciences","year":2025,"doi":"10.3390/medsci13030108"},{"title":"Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial","journal":"The Lancet Oncology","year":2016,"doi":"10.1016/s1470-2045(16)30154-1"},{"title":"Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations","journal":"Nature Communications","year":2017,"doi":"10.1038/ncomms14944"}]},"route":"/people/magdolna-dank/","neighbours":{"institution":[{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","route":"/institutions/noi-budapest/"}],"journal":[{"id":"nature-communications","kind":"journal","name":"Nature Communications","route":"/journals/nature-communications/"},{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/"}]}}